iloprost and Ovarian-Neoplasms

iloprost has been researched along with Ovarian-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for iloprost and Ovarian-Neoplasms

Article	Year
Iloprost, a prostacyclin analog, inhibits the invasion of ovarian cancer cells by downregulating matrix metallopeptidase-2 (MMP-2) through the IP-dependent pathway. Prostaglandins & other lipid mediators, 2018, Volume: 134 Recent studies have shown that a bioactive lipid prostacyclin (PGI Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Down-Regulation; Epoprostenol; Female; Humans; Iloprost; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Receptors, Epoprostenol; Signal Transduction	2018

Article

Year

Iloprost, a prostacyclin analog, inhibits the invasion of ovarian cancer cells by downregulating matrix metallopeptidase-2 (MMP-2) through the IP-dependent pathway.

Prostaglandins & other lipid mediators, 2018, Volume: 134

Recent studies have shown that a bioactive lipid prostacyclin (PGI

Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Down-Regulation; Epoprostenol; Female; Humans; Iloprost; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Receptors, Epoprostenol; Signal Transduction

2018